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ABSTRACT
Objectives A core outcome set (COS) is an agreed 
standardised minimum collection of outcomes that should 
be measured and reported in research in a specific area 
of health. Cochrane systematic reviews (‘reviews’) are 
rigorous reviews on health- related topics conducted under 
the auspices of Cochrane. This study examines the use of 
existing COS to inform the choice of outcomes in Cochrane 
systematic reviews (‘reviews’) and investigates the views 
of the coordinating editors of Cochrane Review Groups 
(CRGs) on this topic.
Methods A cohort of 100 recently published or updated 
Cochrane reviews were assessed for reference to a 
COS being used to inform the choice of outcomes for 
the review. Existing COS, published 2 or more years 
before the review publication, were then identified to 
assess how often a reviewer could have used a relevant 
COS if it was available. We asked 52 CRG coordinating 
editors about their involvement in COS development, how 
outcomes are selected for reviews in their CRG and their 
views of the advantages and challenges surrounding the 
standardisation of outcomes within their CRG.
Results In the cohort of reviews from 2019, 40% (40/100) 
of reviewers noted problems due to outcome inconsistency 
across the included studies. In 7% (7/100) of reviews, a 
COS was referenced in relation to the choice of outcomes 
for the review. Relevant existing COS could be considered 
for a review update in 35% of the others (33/93). Most 
editors who responded (31/36, 86%) thought that COS 
should definitely or possibly be used to inform the choice 
of outcomes in a review.
Conclusions Systematic reviewers are continuing to 
note outcome heterogeneity but are starting to use COS to 
inform their reviews. There is potential for greater uptake 
of COS in Cochrane reviews.
BACKGROUND
Systematic reviews (‘reviews’) of the effects of 
healthcare interventions summarise the avail-
able evidence and are used to inform decision- 
making. Inconsistencies in the outcomes that 
are measured and reported across studies 
included in reviews can mean that it is not 
possible for all studies to be included in a 
meta- analysis; however, a form of research 
waste. In addition, the selective reporting of 
outcomes by some included studies based on 
the direction or magnitude of the results, a 
phenomenon known as outcome reporting 
bias, can affect the robustness of the conclu-
sions of a review.1 2
Furthermore, there is an increasing aware-
ness that differences exist between the 
outcomes measured in clinical trials and 
outcomes that patients consider important. 
For example, only 50% of the outcomes that 
patients said matter to them were captured in 
the clinical trials reviewed by the Canadian 
Agency for Drugs and Technologies in Health 
Strengths and limitations of this study
 ► A sample of 100 Cochrane systematic reviews that 
were published for the first time or updated in 2019 
was assessed.
 ► Two investigators independently assessed the rele-
vance of a core outcome set (COS) to each system-
atic review.
 ► An assumption was made that if a COS had been 
published 2 or more years before the publication of 
the systematic review, it would have been available 
to the reviewers to adopt.
 ► Coordinating editors for all Cochrane Review Groups 
were asked for their views on the relevance of COS 
to systematic reviews.
 ► The research was undertaken before the release 
of V.6 of the Cochrane Handbook for Systematic 
Reviews of Interventions, which recommends that 
Cochrane reviewers should consider using a COS.
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Common Drug Review.3 Such problems also contribute to 
research waste.4
One solution to these problems with the choice of 
outcomes is for clinical trialists in a particular topic area 
to measure and report, at a minimum, a core outcome set 
(COS), which would then be used in reviews addressing 
that same topic area. A COS is an agreed standardised 
collection of outcomes that should be measured and 
reported in a specific area of health. It does not preclude 
the inclusion of additional outcomes, but represents the 
minimum for all research studies in the topic area. The 
scope of a COS refers to the specific area of health or 
healthcare of interest to which the COS is to be applied, 
defined in terms of the health condition, population and 
healthcare interventions covered. Thus, within a partic-
ular topic area there may be multiple COSs, depending 
on whether a COS is developed for different populations, 
for example adults versus children, or localised versus 
advanced disease. A COS may be developed to apply 
to any intervention for that condition, or it may be for 
specific types, for example surgery.
Minimum standards have been established for devel-
oping COS.5 According to these standards, as a minimum, 
the stakeholders who should be involved in developing a 
COS should be those with lived experience of the condi-
tion, health professionals caring for those with lived expe-
rience and those undertaking research in the condition.5
The benefits of widespread adoption of a COS are to 
increase outcome consistency across trials, resulting in a 
major reduction in selective reporting and maximising 
the potential for a trial to contribute to meta- analyses of 
these key outcomes.6 Of crucial importance is that, given 
the expectations of relevant stakeholder involvement, the 
use of a COS should mean trialists are much more likely 
to measure appropriate outcomes that are relevant to 
patients.
An additional issue in the choice of outcomes for a 
systematic review relates to clinical trialists and systematic 
reviewers sometimes being interested in different types 
of outcomes.7 8 Clarke and Williamson have argued for 
greater involvement of systematic reviewers in the devel-
opment and implementation of COS,1 suggesting this 
might help with planning of reviews and ensuring that 
reviews identify data for outcomes of interest.
Cochrane reviews are rigorous systematic reviews 
conducted under the auspices of Cochrane, a global and 
independent volunteer organisation with the primary goal 
of conducting evidence syntheses in health. Cochrane is 
organised operationally into Cochrane Review Groups 
(CRGs), comprised of an editorial team, information 
specialists,and authors responsible for reviews within 
distinct clinical and public health areas. For specific 
reviews, decisions need to be made regarding outcomes 
that will be included in the review as well as the subset of 
key outcomes that will be prioritised for inclusion in the 
summary of findings (SoF) tables. SoF tables are intended 
to provide consumers of the review with the key findings 
of the review.
Each CRG is led by a coordinating editor who oversees 
the production and maintenance of Cochrane reviews. 
In a 2012 survey of CRG coordinating editors (hereafter 
‘editors’), the majority (33/45, 73%) thought that COS 
should routinely be used in the SoF tables.9 At that time, 
a third of the editors (14/45, 31%) reported personal 
involvement in the development of a COS.
The awareness and development of COS have substan-
tially increased over recent years, with more than 100 new 
COS published between 2012 and 2019 and at least 200 
more in development.10–16 A series of guidelines have 
been published to improve the design and reporting of 
COS development.17–20 The relevance of COS to defining 
review questions and planning the review, as well as the 
inclusion of patient- centred outcomes within COS, is 
acknowledged in the 2019 version of the Cochrane Hand-
book for Systematic Reviews of Interventions, which 
states, ‘where available, established sets of core outcomes 
should be used’.21 One notable link between COS devel-
opment and Cochrane is the work of the Cochrane Skin 
Group on the Cochrane Skin Core Outcome Set Initiative 
(CS- COUSIN).22 23 The mission of this group is to stan-
dardise outcomes in dermatology clinical trials in order 
to make trial evidence more comparable and, thereby, 
to strengthen the quality, interpretability and ability of 
systematic reviews to facilitate evidence- based decision- 
making in dermatology.
In this paper, we examine current practices of Cochrane 
systematic reviewers in relation to the use of COS in 
choosing outcomes, and the current views of CRG editors 
regarding the adoption of COS in their CRGs.
METHODS
Assessment of Cochrane reviews in relation to COS
Although a formal protocol was not developed for this 
study, the following approach was agreed among the 
research team in advance. We examined the first 100 new 
or updated Cochrane intervention reviews published in 
2019 (dated 1 January to 8 March). We chose to restrict to 
reviews published in 2019 in order to determine contem-
porary practices regarding outcome choice in Cochrane 
reviews. The sample size was a pragmatic choice, to give 
a reasonable number of reviews that we could assess in a 
reasonable period of time.
We examined whether, in the completed version of 
the review, the review authors: (1) mentioned using a 
COS to choose outcomes for the review, even if all the 
outcomes in the COS may not have been used; (2) identi-
fied any problems with outcome inconsistency across the 
studies included in the review and (3) noted the need 
for development of a COS. We extracted information that 
may have been reported in any section of the completed 
review. One investigator (among IJS, JJK, KH, PRW, RdAO 
and TL) extracted information from each review and one 
investigator (between MC and IJS) verified the extracted 
information.
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For each review, we searched the Core Outcome 
Measures in Effectiveness Trials (COMET) Database (a 
regularly updated online repository of COS studies) to 
establish whether a COS with a relevant scope (even if 
not an exact match) had been published by 31 December 
2016, such that it might have been available to inform 
outcome choice at the planning stage for reviews that 
were published more than 2 years later. For reviews 
where no such COS was found, the COMET Database was 
also searched for COS published since 1 January 2017, 
to determine whether a relevant COS may be available 
for consideration when the Cochrane review is updated. 
Two investigators (SLG and PRW) assessed the potential 
relevance of identified COS independently and then 
compared their assessments, following an approach used 
previously (data available on request).24
Coordinating editors of CRGs
Consistent with the approach used in our 2012 survey,7 we 
emailed the editors of all 52 CRGs (as of 2019) requesting 
them to provide information on their involvement with 
COS development and their CRG policy with regards 
to outcome selection for reviews and prioritisation of 
outcomes for associated SoF tables. They were presented 
with a breakdown of the total number of completed and 
ongoing COS for research, with references, that were 
within the scope of their CRG (figure 1 summarises the 
number of COS by topic area).
This list of COS was compiled from the annual update 
of a review of COS studies conducted by the COMET 
initiative and was last updated in 2018.
Editors were also asked about their opinions on the 
standardisation of outcomes within their CRG, including 
what they thought were up to three main advantages and 
three main challenges of standardising outcomes across 
all reviews in a particular condition covered by their CRG. 
They were provided with the responses from the 2012 
survey for their CRG and were asked to indicate whether 
those earlier responses remained the same or to identify 
any changes of opinion.
Expanding on our 2012 survey, we requested them to 
provide details of any examples where a COS had been 
considered to guide the choice of outcomes to include in 
a Cochrane review or a SoF table. Second, we described 
the aims of the CS- COUSIN initiative and asked editors for 
their views on the relevance and feasibility of establishing 
links between their CRG and an equivalent COS group.
Responses were collected between 26 February and 30 
April 2019. Non- responders were contacted every 3 weeks 
during this period with reminders to participate.
Analysis
The data from the assessment of Cochrane reviews were 
analysed descriptively. The lists of advantages and chal-
lenges of COS suggested by editors was independently 
reviewed by two authors (JJK and PRW) and coded using 
the categories identified in the 2012 survey, allowing new 
categories to be added. Discrepancies in categorisation 
were resolved through discussion.
Figure 1 Published and ongoing core outcome sets according to Cochrane Review Group.
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Patient and public involvement
Patients or the public were not involved in the design, 
conduct or reporting of this research.
RESULTS
Assessment of Cochrane reviews in relation to use of COS to 
inform outcome choice
The reviews assessed addressed a range of health condi-
tions (table 1). Forty- one of the 52 current CRGs (79%) 
were represented. Forty reviews (40%) identified prob-
lems of inconsistency in outcomes in included studies; in 
five of these, the authors also explicitly noted the need for 
development of a COS.
Seven of 100 (7%) reviews mentioned (or cited) a 
COS in relation to choosing outcomes for the review. A 
further three reviews, while not mentioning a COS in 
relation to choosing outcomes for the review and not 
specifically recommending the use of a COS, made obser-
vations about existing COS. One review noted that several 
patient- important outcomes identified in an existing COS 
were absent from most of the review’s included studies. 
One review acknowledged an existing COS, noting that 
the trials in the review continued to report inconsistent 
outcomes, and noted that further work was needed on how 
the outcome domains in the COS should be measured to 
facilitate future reviews. The third review recommended 
that researchers should adopt the definition of a partic-
ular outcome domain of interest to the review as provided 
in an existing COS.
For the 90 reviews not referring to a COS, a relevant 
COS was found to have been published in 2016 or earlier 
in 24 reviews. Thus, of 93 reviews not referencing a COS 
in relation to choosing outcomes for the review, in 27 
(29%) cases, this could have been possible.
In summary, of the 100 reviews, a COS from 2016 or 
earlier was available for 34 reviews (34%). Of those 34 
reviews, a COS was used in 7 reviews (21%). In a further 
six reviews, a relevant COS was published in 2017 or later. 
Thus, a relevant COS could be considered during the 
updating of at least 35% (33/93) of the reviews that have 
not already used a COS.
Editors’ views
Thirty- eight (73%) of the 52 CRG editors responded to 
our emails, although some did not provide a response to 
all questions. Two- thirds of the editors (23/35, 66%) had 
been involved in the development of a COS, 8 editors 
prior to the 2012 survey and 15 since then.
As of 23 April 2019, the COMET Database contained 
323 published and 242 ongoing COS across all CRGs, 
ranging from 0 (hypertension and sexually transmitted 
infections) to 54 (musculoskeletal) (figure 1). The total 
number of published and ongoing COS was slightly higher 
for CRGs whose editors responded in 2019 (median 9, 
IQR 5–16.5) compared with not (median 7, IQR 5–9).
Of 22 editors who responded in both 2012 and 2019, 
64% noted in 2012 that COS should be used in SoF; this 
percentage rose to 91% in 2019.
CRG outcome policies
Figures 2 and 3 show the policies of CRGs for outcome 
selection for reviews (figure 2) and for SoF tables 
(figure 3); both show a reduction in a policy of authors’ 
discretion since 2012, to 49% in 2019. Currently, 40% 
(14/35) of CRGs have a centralised policy for both 
review and SoF table outcome choice. Four editors (11%) 
indicated that outcome choice was now a negotiation 
between authors and the editorial team, with input from 
peer reviewers.
In 2019, half of the editors (18/36; 50%) thought that 
COS should definitely be considered in the process of 
choosing outcomes for an SoF, while a further 13 (36%) 
editors thought that COS could possibly be used in some 
Table 1 Health conditions addressed in the 100 Cochrane 
reviews assessed in relation to use of COS
ICD-11 
code Disease area N (%)
12 Respiratory system 11 (11)
16 Genitourinary system 11 (11)
2 Neoplasms 9 (9)
11 Circulatory system 8 (8)
1 Infectious or parasitic diseases 5 (5)
8 Nervous system 5 (5)
13 Digestive system 4 (4)
15 Musculoskeletal system 4 (4)
9 Visual system 4 (4)
14 Skin 3 (3)
24 Factors influencing health status or 
contact with health services
3 (3)
4 Immune system 2 (2)
5 Endocrine, nutritional or metabolic 
diseases
2 (2)
6 Mental, behavioural or 
neurodevelopmental
2 (2)
7 Sleep–wake disorders 2 (2)
17 Conditions related to sexual health 2 (2)
3 Blood or blood- forming organs 1 (1)
10 Ear or mastoid process 1 (1)
19 Certain conditions originating in the 
perinatal period
1 (1)
21 Symptoms, signs or clinical findings, 
not elsewhere classified
1 (1)
22 Injury, poisoning or certain other 
consequences of external causes
1 (1)
23 External causes of morbidity or 
mortality
1 (1)
No specific 
ICD-11 
code
Miscellaneous 17 (17)
ICD-11, International Classification of Diseases 11th Revision.
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circumstances if relevant to the specific review and if the 
COS was developed using a ‘quality’ consensus approach. 
Two (6%) editors thought that COS should not be used 
in the SoF tables because they can lead to the inclusion 
of unnecessary outcomes. One editor did not think that 
the inclusion of COS in SoF tables was relevant, because 
they did not think COS were used in their topic area. Two 
editors were unsure because they were aware that many 
COS contain more than the maximum of seven outcomes 
that Cochrane allows for SoF tables.
Advantages and challenges of standardising outcomes in Cochrane 
reviews
For both the advantages and challenges associated with 
standardising outcomes across reviews (table 2), the 
three most commonly listed were the same as in the 2012 
survey. Just under half of the editors consider an advan-
tage of using a COS to be that the outcomes are likely to 
be more appropriate.
One notable difference from 2012 was a shift from the 
most frequently listed challenge being COS development 
(55% in 2012, falling to third place on 22% in 2019) to 
deciding when a COS should be applied (in relation to 
the scope of the review and the scope of the COS) in 
2019 (78%). One new challenge identified in 2019 by 
three editors (8%) was the perception that the use of a 
COS may limit review authors due to a lack of flexibility 
in outcome choice.
Links between CRG, COS developers and guidance
Eight editors identified cases where the outcome choice 
in at least one review in their group had been informed 
by a COS. The majority (22/26, 85%) of editors thought 
that links between their CRG and COS developers in 
their field would be a good idea in principle, while four 
could see no benefit. In addition to the Cochrane Skin 
Group, three CRGs had already established such links: 
the Cochrane Musculoskeletal Group with the Outcome 
Measures in Rheumatology initiative,25 the Cochrane 
Kidney and Transplant Group with the Standardising 
Outcomes in Nephrology initiative26 and the Cochrane 
Pregnancy and Childbirth Group with the Core Outcomes 
in Women’s and Newborn Health initiative.27
The major perceived barriers to establishing links 
between CRGs and COS developers were related to 
Figure 2 CRG outcome choice policies. Denominators are 
(n=45) and (n=35) for 2012 and 2019, respectively. CRG, 
Cochrane Review Group.
Figure 3 CRG SoF table choice policies. Denominators 
are (n=45) and (n=35) for 2012 and 2019, respectively. CRG, 
Cochrane Review Group; SoF, summary of findings.
Table 2 Views of Cochrane editors on standardising 
outcomes across all reviews for a particular condition
Advantages
2012
n/40 (%*)
2019
n/32 (%*)
Advantage for a systematic review/
meta- analysis
39 (98) 27 (84)
Improves interpretation/guidance 19 (48) 7 (22)
Outcome likely to be more 
appropriate
16 (40) 10 (45)
Advantage for the design of a new 
study
13 (33) 5 (16)
Improves something about the 
outcome itself (eg, simplifies the 
reporting)
6 (15) 0 (0)
Reduces outcome reporting bias 6 (15) 1 (3)
Reduces resource requirement (eg, 
time to review)
1 (3) 1 (3)
Challenges 2012
n/42 (%*)
2019
n/36 (%*)
Development of a COS 23 (55) 8 (22)
Something about scope 21 (50) 28 (78)
How to persuade authors/trialists/
industry to implement
20 (48) 14 (39)
‘How’ to measure once the ‘what’ 
has been decided
11 (26) 3 (8)
Important outcomes not currently 
being measured
2 (5) 1 (3)
Resource to develop 2 (5) 3 (8)
Updating process 2 (5) 2 (6)
Conflict of interest 1 (1) 0 (0)
Limits authors 0 (2) 3 (8)
*Percentages represent the number of Cochrane Review Group 
coordinating editors who mentioned each advantage/challenge.
COS, core outcome set.
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lack of resources, mainly lack of time (mentioned nine 
times) and funding to coordinate (mentioned five times). 
Conflicts of interest, the potential for poor communica-
tion between members and lack of knowledge on how to 
manage such links were also quoted as potential barriers 
to implementation.
CONCLUSIONS
Our study has demonstrated that Cochrane systematic 
reviewers note widespread outcome inconsistency across 
studies. We found that almost all CRG editors think that 
COS should definitely or possibly be used in SoF tables, 
and that reviewers are beginning to use COS to inform 
their choice of outcomes.
We have documented an increased level of involvement 
of CRG editors in COS development studies since 2012. 
The COS- STAD (Core Outcome Set- Standards for Devel-
opment) guidance identifies three stakeholder groups as 
the minimum for input into the development of a COS: 
patients or their representatives, healthcare professionals 
and those who will use the COS in research.17 Consensus 
was not quite achieved that a fourth group, those who will 
use the research that should use the COS (eg, systematic 
reviewers, guideline developers, policy makers and regu-
latory agencies), should always be involved. COS- STAD 
participants may have wanted to avoid setting a minimum 
standard when there was limited experience of engaging 
with these particular stakeholder groups. If the involve-
ment of Cochrane reviewers in COS development studies 
continues to increase, it would seem appropriate to review 
the standard in due course.
The majority of editors were in favour of coopera-
tion between their CRG and COS developers in their 
field; however, the most frequently mentioned potential 
barriers, such as lack of time, resources and funding, will 
need to be addressed to achieve this. The affiliation of a 
COS development initiative to a CRG, as with CS- COUSIN 
in dermatology,22 23 could offer easier access to informa-
tion about outcomes previously measured in trials, and to 
Cochrane’s international network of consumers, health-
care professionals and researchers in the field. Addi-
tionally, close interaction between COS development 
and CRGs should support COS implementation. For the 
dermatology outcome research community, the formal 
affiliation of COS development groups to Cochrane is 
considered an important advantage. This strategy has led 
to the affiliation of 15 COS groups to CS- COUSIN since 
its initiation in 2015.22 23
Our study has some limitations. No formal protocol 
was developed for this study; however, the research 
team had agreed the methodological approach prior to 
commencing the study.
Second, we achieved a 73% response rate from CRG 
coordinating editors. While this rate is acceptable, it is 
conceivable that non- response bias may have arisen as a 
result of a lack of interest or awareness about COS among 
editors not responding. A third limitation may have 
been our assumption that if a COS had been published 
2 or more years before the publication of the system-
atic review, it would have been available to the reviewers 
to adopt. This may not have always been true. Previous 
studies have found that reviews generally,28 and Cochrane 
reviews specifically,29 take an average of less than 2 and 
2.4 years to be completed, respectively. This suggests that 
our assumption regarding availability of the COS to the 
systematic reviewers may not be unreasonable.
Cochrane now recommends that reviewers should 
consider using COS where these exist.18 Our study iden-
tifies some implications for practice when following this 
guidance. The COMET database of COS (available online 
at http://www. comet- initiative. org/) is free, searchable 
and covers a range of health fields. Using a given COS 
for a given systematic review involves, at the least, an 
assessment of the appropriateness of the topic, scope, 
stakeholder representation and currency of the COS. We 
recommend that, when a potentially appropriate COS 
exists for a given systematic review, the authors should 
either use it to inform their choice of outcomes or justify 
their reason for not using it. In addition, authors of 
Cochrane reviews, especially those that identify outcome 
inconsistency in included studies, should take the oppor-
tunity to move their respective fields forward by explicitly 
noting the need for COS, recommending COS develop-
ment and participating in the COS development process.
Our study has some implications for research. The 
assessment presented here will act as a benchmark for 
subsequent evaluation of the implementation of the guid-
ance in the Cochrane Handbook that is specific to using 
COS when choosing outcomes for Cochrane reviews. We 
note that 66% of the review topics, from 31 CRGs, did 
not have a relevant COS. Future research should include 
identification of priority areas for COS development.
The use of COS for a systematic review in turn may influ-
ence clinical trialists to use that same COS to ensure that 
their trials can contribute fully to subsequent reviews and 
meta- analyses. Given the continued problem of outcome 
inconsistency in studies documented in Cochrane reviews, 
and the fact that four CRGs have already established links 
to COS development groups, this topic could be a poten-
tial area for strategic development of Cochrane. Such 
greater uptake of COS across the healthcare research 
ecosystem could help improve research and thereby 
improves healthcare and health.
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